Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread
- Hung Chih Hsu
- , Kuo Cheng Huang
- , Wei-Shone Chen
- , Jeng Kai Jiang
- , Shung-Haur Yang
- , Huann Sheng Wang
- , Shih-Ching Chang
- , Yuan Tzu Lan
- , Chun Chi Lin
- , Hung Hsin Lin
- , Sheng Chieh Huang
- , Hou Hsuan Cheng
- , Tsai Sheng Yang
- , Chien Chih Chen
- , Yee Chao
- , Hao Wei Teng*
*此作品的通信作者
研究成果: Article › 同行評審
9
引文
斯高帕斯（Scopus）